PGP:NYE-Pimco Global Stocksplus & Income Fund StocksPlus & Income Fund of Beneficial Interest (USD)

ETF | Biotechnology | New York Stock Exchange

Last Closing

USD 7.42

Change

0.00 (0.00)%

Market Cap

USD 0.17B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment objective is to seek total return comprised of current income, current gains and long-term capital appreciation. The objective is normally attempted to achieve by investing in equity index derivative instruments that have economic characteristics similar to U.S. and non-U.S. common stocks and that provide equity index exposure equal to 80% of the net assets. The Fund ordinarily expects to maintain equity index exposure equal to approximately 100% of the net assets (initially approximately 50% U.S. and 50% non-U.S.), thereafter, those percentages are expected to vary. The Fund may invest up to 30% of the total assets in emerging markets. Equity index derivative positions are backed by an actively-managed, low duration (one to three year) debt portfolio with an average credit quality that is investment grade. The Fund currently intends to gain substantially all of its equity index exposure by investing in equity index derivatives based on the S&P 500 Index and the MSCI EAFE Index. A strategy of writing (selling) call options on U.S. equity indexes will also be employed. Substantially all of the assets ordinarily will be invested in a portfolio of income-producing debt-securities and debt-related derivative securities.

Inception Date: 31/05/2005

Primary Benchmark: MSCI Europe NR USD

Primary Index: MSCI ACWI Ex USA NR USD

Gross Expense Ratio: 2.75%

Management Expense Ratio:

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Biotechnology

Symbol Name Mer Price(Change) Market Cap
NVO Novo Nordisk A/S 0.00 %

N/A

USD 567.03B
BHVN Biohaven Pharmaceutical Holdin.. 0.00 %

N/A

USD 3.15B
HTD John Hancock Tax Advantaged Di.. 0.00 %

N/A

USD 2.41B
DNA Ginkgo Bioworks Holdings 0.00 %

N/A

USD 1.68B
RCUS Arcus Biosciences Inc 0.00 %

N/A

USD 1.41B
NUVB Nuvation Bio Inc 0.00 %

N/A

USD 0.64B
ADCT ADC Therapeutics SA 0.00 %

N/A

USD 0.36B
CYBN Cybin Inc 0.00 %

N/A

USD 0.29B
ATNM Actinium Pharmaceuticals Inc 0.00 %

N/A

USD 0.26B
LCTX Lineage Cell Therapeutics Inc 0.00 %

N/A

USD 0.20B

ETFs Containing PGP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.07% 57% F 39% F
Dividend Return 3.68% 80% B- 94% A
Total Return 2.61% 57% F 53% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return 11.16% 100% F 95% A
Total Return 11.16% 61% D- 56% F
Trailing 5 Years  
Capital Gain -40.35% 22% F 14% F
Dividend Return 35.66% 60% D- 90% A-
Total Return -4.70% 33% F 25% F
Average Annual (5 Year Horizon)  
Capital Gain -7.87% 51% F 12% F
Dividend Return 1.45% 57% F 35% F
Total Return 9.32% 100% F 96% N/A
Risk Return Profile  
Volatility (Standard Deviation) 24.56% 86% B+ 46% F
Risk Adjusted Return 5.92% 57% F 31% F
Market Capitalization 0.17B 80% B- 39% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.